Airfinity shortlisted at the Reuters Pharma Awards 2022
Posted on Sep 12, 2022
Airfinity has been shortlisted for Most Valuable Data & Insights Initiative at the Reuters Pharma Awards 2022 for its work supporting governments and pharma in the global response to COVID-19.
It is an honour to be recognised alongside fellow finalists AstraZeneca, Novartis, CREATION.co and ATMPS.
View the full list of shortlisted companies here.
To request more information about our work in COVID-19 and infectious diseases, get in touch here.
More Insights From Airfinity
Introducing Airfinity Biorisk: Risk Surveillance and Analytics for 160+ Infectious Diseases
Oct 10, 2022
18 million monkeypox vaccines needed to protect most at risk, 85 million to protect wider gay community and health workers
Aug 25, 2022
Sales of COVID-19 antiviral pill Paxlovid to leap frog Merck’s competitor Molnupiravir
Jul 25, 2022
COVID-19 vaccines sales to bounce back with new jabs taking a fifth of the 2022 market
Jul 15, 2022
AstraZeneca and Pfizer/BioNTech saved over 12 million lives in the first year of vaccination
Jul 13, 2022
Global wastage of COVID-19 vaccines could be 1.1 billion doses
Jul 11, 2022